Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2000

View Archived Issues

SmithKline Beecham launches Abreva in U.S.; Avanir receives milestone payment

EMEA recommends approval of Reductil for management of obesity

ABX-CBL granted orphan drug status for treatment of acute GVHD

Biological activity of new member of VEGF family confirmed by Collateral Therapeutics

NXY-059 to enter phase I trials as a potential treatment for acute stroke in Japan

CAT grants Immunex license related to development of novel human MAbs

Phase I trial of new treatment for HCV and associated liver cancer cleared in Israel

BioStratum and Shire collaborate on XR formulation of Pyridorin

Neuroprotective effects demonstrated in vitro and in vivo for new caspase inhibitor

Antagonism of neuropeptide Y1 receptors protects against focal cerebral ischemia

Multiple doses of BMS-204352 safe and well tolerated in acute stroke patients

Beneficial effects of AM-36 against veratridine-induced neuronal injury suggest potential in stroke

Proteasome inhibition as a novel approach to stroke: initial clinical results for PS-519

CDK-inhibitory pyrazolobenzodiazepines for cancer

New PARP inhibitors presented by BASF for use in neurological, neurodegenerative disorders

Nelarabine + fludarabine has significant activity, acceptable toxicity in refractory leukemias

Inhibitors of NHE and their use in cardiovascular disorders claimed by BMS

Japanese patent covers new steroidal antiproliferative compounds identified at Kaneka

Carbapenems with good oral bioavailability prepared by Sankyo researchers

Kyowa Hakko reveals newest inhibitors of PDE5 and their potential therapeutic applications

Korean researchers discover new series of protein farnesyltransferase inhibitors

Novel series of tricyclic osteogenesis promoters patented by Taisho

Preliminary data reported from two Insmed diabetes clinical trials

Phase I safety and pharmacokinetic analysis of AP-1903 reported at Hematology meeting

Cubist acquires rights to oral ceftriaxone

Recombinant urate oxidase is a safe and effective uricolytic agent in hematological malignancies

Novel Gardos channel inhibitor improves RBC dehydration and sickling in transgenic mouse model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...